{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T21:23:44Z","timestamp":1758403424367},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T00:00:00Z","timestamp":1562544000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00125-019-4945-7","type":"journal-article","created":{"date-parts":[[2019,7,8]],"date-time":"2019-07-08T21:35:30Z","timestamp":1562621730000},"page":"1730-1731","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Reply to Pagni PP, Wolf A, Lo Conte M et al [letter]"],"prefix":"10.1007","volume":"62","author":[{"given":"Gisela M.","family":"Vaitaitis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael H.","family":"Olmstead","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan M.","family":"Waid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica R.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"David H.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,8]]},"reference":[{"key":"4945_CR1","doi-asserted-by":"publisher","unstructured":"Pagni PP, Wolf A, Lo Conte M et al (2019) CD40-targeted peptide proposed for type 1 diabetes therapy lacks relevant binding affinity to its cognate receptor. Diabetologia. \n                    https:\/\/doi.org\/10.1007\/s00125-019-4893-2","DOI":"10.1007\/s00125-019-4893-2"},{"issue":"11","key":"4945_CR2","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1007\/s00125-014-3342-5","volume":"57","author":"GM Vaitaitis","year":"2014","unstructured":"Vaitaitis GM, Olmstead MH, Waid DM, Carter JR, Wagner DH Jr (2014) A CD40-targeted peptide controls and reverses type 1 diabetes in NOD mice. Diabetologia 57(11):2366\u20132373. \n                    https:\/\/doi.org\/10.1007\/s00125-014-3342-5","journal-title":"Diabetologia"},{"issue":"4","key":"4945_CR3","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.1073\/pnas.98.4.1751","volume":"98","author":"M Tone","year":"2001","unstructured":"Tone M, Tone Y, Fairchild PJ, Wykes M, Waldmann H (2001) Regulation of CD40 function by its isoforms generated through alternative splicing. Proc Natl Acad Sci U S A 98(4):1751\u20131756. \n                    https:\/\/doi.org\/10.1073\/pnas.98.4.1751","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"4945_CR4","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1016\/j.molimm.2010.05.288","volume":"47","author":"GM Vaitaitis","year":"2010","unstructured":"Vaitaitis GM, Wagner DH Jr (2010) CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Mol Immunol 47(14):2303\u20132313. \n                    https:\/\/doi.org\/10.1016\/j.molimm.2010.05.288","journal-title":"Mol Immunol"},{"issue":"6","key":"4945_CR5","doi-asserted-by":"publisher","first-page":"e38708","DOI":"10.1371\/journal.pone.0038708","volume":"7","author":"GM Vaitaitis","year":"2012","unstructured":"Vaitaitis GM, Wagner DH Jr (2012) Galectin-9 controls CD40 signaling through a Tim-3 independent mechanism and redirects the cytokine profile of pathogenic T cells in autoimmunity. PLoS One 7(6):e38708. \n                    https:\/\/doi.org\/10.1371\/journal.pone.0038708","journal-title":"PLoS One"},{"key":"4945_CR6","doi-asserted-by":"publisher","unstructured":"Vaitaitis GM, Wagner DH Jr (2013) CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression. Cell Mol Immunol 10(6):483\u2013489. \n                    https:\/\/doi.org\/10.1038\/cmi.2013.24","DOI":"10.1038\/cmi.2013.24"},{"issue":"13","key":"4945_CR7","doi-asserted-by":"publisher","first-page":"11226","DOI":"10.1074\/jbc.M110.208215","volume":"286","author":"HJ An","year":"2011","unstructured":"An HJ, Kim YJ, Song DH et al (2011) Crystallographic and mutational analysis of the CD40-CD154 complex and its implications for receptor activation. J Biol Chem 286(13):11226\u201311235. \n                    https:\/\/doi.org\/10.1074\/jbc.M110.208215","journal-title":"J Biol Chem"},{"key":"4945_CR8","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jneuroim.2019.03.013","volume":"332","author":"GM Vaitaitis","year":"2019","unstructured":"Vaitaitis GM, Yussman MG, Wagner DH Jr (2019) A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis. J Neuroimmunol 332:8\u201315. \n                    https:\/\/doi.org\/10.1016\/j.jneuroim.2019.03.013","journal-title":"J Neuroimmunol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00125-019-4945-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-019-4945-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,8]],"date-time":"2020-07-08T00:08:30Z","timestamp":1594166910000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00125-019-4945-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,8]]},"references-count":8,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["4945"],"URL":"https:\/\/doi.org\/10.1007\/s00125-019-4945-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,8]]},"assertion":[{"value":"29 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"DHW is the founder and Chief Science Officer of Op-T LLC. DMW is the Chief Financial Officer of Op-T LLC. GMV performs consulting work for Op-T LLC.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Duality of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}